Worldwide Contraceptive Devices Industry to 2025 - Players Include Allergan Plc, Bayer Healthcare and Cooper Surgical Among Others
04 févr. 2021 06h48 HE
|
Research and Markets
Dublin, Feb. 04, 2021 (GLOBE NEWSWIRE) -- The "Contraceptive Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
14 mars 2018 07h45 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for...
Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
12 mars 2018 16h15 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three months and year ended...
Global Intra-Uterine Contraceptive Device (IUDs), a Safer Way to Birth Control Measure with Reversible Contraception is Expected to Reach USD 5.27 Billion by 2023
31 janv. 2018 06h49 HE
|
Energias Market Research
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- The global intra-uterine contraceptive device market is expected to grow steadily from USD 3.80 billion in 2016 to USD 5.27 billion in 2023, at a CAGR of...
Agile Therapeutics to Host First Analyst Day on October 10, 2017
02 oct. 2017 07h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday,...
Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
03 août 2017 08h23 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced the pricing of its underwritten public...
Agile Therapeutics Announces Proposed Offering of Common Stock
02 août 2017 16h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that it intends to offer and sell shares of...
Agile Therapeutics Reports Second Quarter 2017 Financial Results
28 juil. 2017 07h30 HE
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
27 juil. 2017 16h11 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...
Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®
27 juin 2017 08h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration...